Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib vs Carboplatin/Vincristine in NF1-Associated Low-Grade Glioma
NCT03871257Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of selumetinib in glioma, neurofibromatosis type 1 (NF1) and Visual pathway glioma (OPG) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Event-free survival and Visual acuity improvement at 12 months. Started Jan 2020; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
gliomaneurofibromatosis type 1 (NF1)Visual pathway glioma (OPG)
Beyond the preview
Go deeper on NCT03871257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871257.